SCHEMBL8723743

SCHEMBL8723743

O=C(Nc1ccc2scc(C3CCC4CCCCN4CC3)c2c1)c1ccco1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.47
KDM4E B2RXH2 6/20 0.47
HSD17B10 Q99714 6/20 0.47
CASP1 P29466 3/20 0.47
CASP7 P55210 1/20 0.47
MCL1 Q07820 1/20 0.47
NPC1 O15118 6/20 0.46
RAB9A P51151 6/20 0.46
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 9/20 0.44
LMNA P02545 5/20 0.44
MAPK1 P28482 3/20 0.44
TP53 P04637 3/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
ABL1 P00519 1/20 0.44
BCR P11274 1/20 0.44
POLB P06746 1/20 0.42
MEN1 O00255 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8725928 0.86 RORC (0.47) MAPTNPC1RAB9ASMN1; SMN2MAPK1
SCHEMBL8721836 0.84 TMIGD3 (0.41) RAB9A
SCHEMBL8721795 0.84 KMT2A (0.46) MAPTHSD17B10NPC1RAB9AALDH1A1
SCHEMBL8721187 0.83 TDP1 (0.38) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL30909070 0.83 TDP1 (0.38) MAPTSMN1; SMN2POLBMEN1KMT2A
SCHEMBL30908934 0.83 ALDH1A1 (0.44) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL8723596 0.83 ALDH1A1 (0.44) MAPTKDM4ENPC1RAB9AALDH1A1
SCHEMBL8723856 0.82 HTR1D (0.50) NPC1RAB9ASMN1; SMN2MAPK1TP53
SCHEMBL8724094 0.82 ACKR3 (0.39) NPC1RAB9AKMT2AHPGD
SCHEMBL8552316 0.82 NPC1 (0.54) MAPTKDM4EHSD17B10CASP1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
WO-2024073845-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ, LIMITED PARTNERSHIP (CA) 2024-04-11 WO disclosed
EP-0875513-A1 Substituted heteroaromatic 5-HT 1F agonists ELI LILLY AND COMPANY (US) 1998-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D MAPT 3544/4885KDM4E 3551/4885HSD17B10 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.